BPC-157
Also known as: Body Protection Compound 157 · PL-10 · PLD-116 · Bepecin
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. In preclinical research, it is studied for pleiotropic tissue-healing effects across tendons, ligaments, muscle, and the gastrointestinal lining. It is a research compound and is not approved by the FDA for human use.
What is BPC-157?
BPC-157 Structural and Biochemical Profile
BPC-157, or Body Protection Compound 157, is a synthetic pentadecapeptide composed of 15 amino acids in the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). This sequence is derived from a naturally occurring protective protein segment isolated from human gastric juice, highlighting its endogenous origin and potential physiological relevance. Unlike many peptides which undergo rapid degradation in the gastrointestinal tract, BPC-157 exhibits remarkable stability in acidic environments such as gastric acid. This property is notable because it suggests a unique resilience to proteolytic enzymes and acidic hydrolysis, facilitating its bioactivity in digestive tissues during research investigations.
In research settings, BPC-157 is typically synthesized via solid-phase peptide synthesis (SPPS) to ensure high purity and batch-to-batch consistency. Research-grade BPC-157 is characterized by rigorous quality control, including high-performance liquid chromatography (HPLC) purity assessments exceeding 95%, mass spectrometry verification, and endotoxin testing to confirm suitability for preclinical experimentation. At Verified Peptides, we ensure our BPC-157 meets stringent USP-referenced purity standards to support reproducibility and reliability in scientific studies.
From a regulatory perspective, BPC-157 is not FDA-approved for human therapeutic use. It is currently under advisory review by the FDA in 2026, a process that involves comprehensive evaluation of its safety, pharmacokinetics, and potential clinical applications based on aggregated preclinical and any emerging clinical data. This review status underscores the evolving research interest and the need for continued rigorous investigation. Researchers should interpret findings within the context of preclinical data and await regulatory guidance before considering translational applications.
For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.
Key Benefits & Mechanisms
Mechanism of action
Proposed Mechanisms of Action of BPC-157 in Research Contexts
Extensive preclinical research has elucidated multiple putative mechanisms of BPC-157’s biological activity, although the precise molecular pathways remain under investigation. A prominent area of study focuses on BPC-157’s modulation of the nitric oxide (NO) system. Experimental models suggest that BPC-157 influences endothelial nitric oxide synthase (eNOS) expression and activity, potentially regulating vascular tone and microcirculatory function. This modulation may contribute to observed effects on angiogenesis and tissue repair in animal models.
Another research avenue involves interactions between BPC-157 and growth hormone receptor signaling pathways. Some in vitro studies indicate that BPC-157 may influence receptor expression or downstream signaling cascades associated with cellular proliferation and regeneration, although these findings require further validation and mechanistic clarification.
Angiogenesis, the formation of new blood vessels, is a critical process investigated in relation to BPC-157. Multiple rodent studies have demonstrated upregulation of vascular endothelial growth factor (VEGF) and related receptor pathways in response to BPC-157 administration, implicating it in enhanced neovascularization during tissue repair. This VEGF pathway modulation aligns with observed improvements in vascular integrity and blood flow in damaged tissues.
Research focusing on tendon fibroblasts has identified BPC-157’s capacity to stimulate fibroblast proliferation and extracellular matrix remodeling. In vitro and in vivo models highlight its potential to enhance collagen synthesis and organization, which are pivotal in tendon healing processes. Similarly, gastrointestinal research models have explored BPC-157’s role in preserving gut mucosal integrity, potentially via cytoprotective effects and modulation of inflammatory mediators, although mechanisms remain under active study.
Collectively, these mechanistic investigations position BPC-157 as a multifaceted peptide with complex biological interactions, supporting its continued evaluation in diverse preclinical paradigms. It is important to emphasize that these findings are experimental and should not be construed as evidence for clinical efficacy.
For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.
Research Summary
Comprehensive Overview of BPC-157 Research Applications and Scientific Status
BPC-157 is among the most extensively studied regenerative peptides in preclinical literature, with research encompassing multiple tissue types and biological systems. The most robust body of evidence pertains to tendon and ligament repair models. Animal studies, predominantly in rodents, have demonstrated accelerated healing of surgically injured tendons and ligaments following administration of BPC-157. Histological analyses reveal enhanced fibroblast activity, collagen deposition, and neovascularization within the extracellular matrix. These findings have been documented in peer-reviewed journals indexed on PubMed, underscoring reproducibility and methodological rigor.
Gastrointestinal research has explored BPC-157’s capacity to mitigate mucosal damage induced by various insults, including nonsteroidal anti-inflammatory drugs (NSAIDs), ethanol, and ischemia-reperfusion injury. Rodent models illustrate improved mucosal regeneration, reduced ulcer formation, and modulation of inflammatory cytokine profiles. These effects are hypothesized to be mediated via cytoprotective signaling and vascular support mechanisms.
Neurological applications are an emerging area of investigation. Preclinical studies have assessed BPC-157’s influence on nerve regeneration, neuroinflammation, and functional recovery following peripheral nerve injury or central nervous system insults. While data remain preliminary, they suggest potential neuroprotective and regenerative properties warranting further exploration.
Wound healing research has similarly reported accelerated closure of cutaneous wounds and improved granulation tissue formation in animal models treated with BPC-157. These outcomes align with its angiogenic and fibroblastic stimulatory effects. Bone research, though less extensive, indicates that BPC-157 may facilitate bone repair and remodeling processes, as evidenced by enhanced osteoblast activity and callus formation in fracture models.
It is critical to note that BPC-157 remains under FDA advisory review slated for 2026. This regulatory context reflects the peptide’s transition from exploratory research toward potential therapeutic consideration, pending comprehensive safety and efficacy evaluations. Until formal approval is granted, BPC-157 is available exclusively for research purposes, and investigators are advised to source peptides with verified Certificates of Analysis (COA) to ensure experimental integrity.
Collectively, the research corpus on BPC-157 is accessible through PubMed and NIH repositories, providing a robust foundation for ongoing and future investigations. At Verified Peptides, we prioritize supplying high-purity, rigorously tested BPC-157 to facilitate reproducible and reliable scientific inquiry.
For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. (2025) PubMed · PMID 40005999
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. (2019) PubMed · PMID 30915550
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. (2025) PubMed · PMID 40756949
Dosing in Research Literature
Preclinical Research Dosing Parameters for BPC-157
Published animal studies investigating BPC-157 typically employ a range of dosing protocols adapted to specific experimental designs. Administration routes include intraperitoneal (IP), subcutaneous (SC), oral (PO), and occasionally intravenous (IV) injections, with dosages scaled according to animal weight and study objectives. For example, rodent models often utilize doses ranging from microgram to low milligram per kilogram levels, administered once daily or multiple times over several days to weeks.
It is imperative to emphasize that these dosing regimens are established solely for preclinical research contexts and are not indicative of safe or effective human dosages. No standardized human protocols exist, and efficacy or safety data in humans remain unverified.
Researchers typically select doses based on prior literature benchmarks, aiming to elucidate pharmacodynamic and pharmacokinetic profiles as well as biological effects in target tissues. Some studies explore dose-response relationships to identify optimal concentrations for inducing measurable outcomes such as enhanced angiogenesis, fibroblast proliferation, or mucosal protection.
At Verified Peptides, we recommend that investigators rigorously design their experimental protocols, considering peptide purity, stability, and administration routes to maximize data validity. All research should comply with institutional animal care and use guidelines and regulatory requirements.
For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.
The figures above describe doses reported in published or preclinical research, provided for context only. This is not medical advice or a dosing recommendation, and these compounds are not approved for human use.
Common Stacks
Frequently asked questions about BPC-157
What is BPC-157 and where does it originate from?
BPC-157 is a synthetic peptide composed of 15 amino acids, derived from a naturally occurring protective protein segment found in human gastric juice. It is widely studied in preclinical research for its potential regenerative properties.
Is BPC-157 approved by the FDA for human use?
No, BPC-157 is not FDA-approved for human consumption. It is currently under FDA advisory review expected in 2026. Until then, it is available solely for research purposes.
What are the primary research applications of BPC-157?
Research primarily focuses on tendon and ligament regeneration, gastrointestinal mucosal protection, angiogenesis, neurological repair, wound healing, and bone remodeling, among other biological investigations.
How is BPC-157 typically administered in research studies?
In preclinical models, BPC-157 is administered through various routes including intraperitoneal, subcutaneous, oral, and sometimes intravenous injections, with dosing protocols tailored to specific study designs.
Why is peptide purity important for research?
High purity ensures reproducibility and reliability of experimental results. Verified Peptides provides BPC-157 with Certificates of Analysis (COA) confirming purity levels above 95%, critical for scientific investigations.
What does the FDA 2026 review mean for researchers?
The FDA review scheduled for 2026 involves comprehensive evaluation of BPC-157’s safety and potential clinical applications. Researchers should continue to rely on preclinical data and verified sources until regulatory decisions are finalized.
Legal & research status: Research use only — not approved by the FDA for human use. Temporarily banned by the World Anti-Doping Agency (WADA) in 2022; not currently listed as banned. Sold and discussed for laboratory and research use only, not for human consumption.